Chemotherapy drug delivery from calcium phosphate nanoparticles.
Calcium phosphate nanoparticles (nanoCaP) conjugated with cis-diamminedichloroplatinum (CDDP, cisplatin) were prepared through the electrostatic binding of an aquated species of cisplatin to the nanoCaP in a chloride-free solution. The agglomeration of the nanoCaP that typically occurs during synthesis of CaP was controlled through the addition of DARVAN 811 immediately after precipitation and before drug conjugation. In vitro drug release studies were completed and showed a sustained release of CDDP from the nanoconjugates over time. The cytotoxicity of the nanoCaP/CDDP was compared to that of the free drug in an in vitro cell proliferation assay using the CDDP resistant A2780cis human ovarian cancer cell line. The CDDP released from the nanoconjugates was equally effective as the free drug against the A2780cis cell line. Direct addition cytotoxicity studies revealed that the sterically-stabilized, negatively-charged drug nanoconjugates are unable to overcome drug resistance and had an increased IC50 value as compared to the free drug.
Cheng
Xingguo
X
Oral Rehabilitation, Biomaterials and Skeletal Development, University of Connecticut Health Center, Farmington, CT 06030-1615, USA.
Kuhn
Liisa
L
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D002130:Calcium Phosphates / Q000737:chemistry*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry*; D004058:Diffusion; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D006801:Humans; D008422:Materials Testing; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology*; D010316:Particle Size
D000970:Antineoplastic Agents; D002130:Calcium Phosphates; D004337:Drug Carriers; C020243:calcium phosphate; D002945:Cisplatin